Literature DB >> 22495706

Radiotherapy for inoperable non-small cell lung cancer using helical tomotherapy.

Alessia Monaco1, Cristina Caruso, Daniela Giammarino, Michele Cianciulli, Maria Cristina Pressello, Vittorio Donato.   

Abstract

AIM: To investigate the impact of tomotherapy on the dose delivered to the lungs and other normal tissues.
MATERIAL AND METHODS: From February 2008 to May 2009, 35 patients with stage IIIA/IIIB non-small cell lung cancer were treated with helical tomotherapy at the S. Camillo-Forlanini Hospital. For our study we selected 20 patients who underwent chemotherapy followed by sequential radiotherapy. The planning target volume was delineated using planning CT scan and FDG-PET. The mean prescribed radiation dose was 67.5 Gy delivered in 30 fractions at a dose of 2.25 Gy per fraction.
RESULTS: Median follow-up was 12.3 months. All patients developed acute esophageal toxicity, 15 of RTOG grade 1 and 5 of RTOG grade 2. At first follow-up 15 patients presented stable disease or partial response, 4 patients presented complete response, and 1 patient presented disease progression.
CONCLUSIONS: Helical tomotherapy is useful to achieve dose-per-fraction escalation without increasing the treatment-related morbidity. Our results applying dose escalation were encouraging considering that we delivered doses that may be difficult to achieve with 3-dimensional treatments with no excessive complication rates.

Entities:  

Mesh:

Year:  2012        PMID: 22495706     DOI: 10.1177/030089161209800111

Source DB:  PubMed          Journal:  Tumori        ISSN: 0300-8916


  1 in total

1.  Moderately Escalated Hypofractionated (Chemo) Radiotherapy Delivered with Helical Intensity-Modulated Technique in Stage III Unresectable Non-Small Cell Lung Cancer.

Authors:  Vittorio Donato; Stefano Arcangeli; Alessia Monaco; Cristina Caruso; Michele Cianciulli; Genoveva Boboc; Cinzia Chiostrini; Roberta Rauco; Maria Cristina Pressello
Journal:  Front Oncol       Date:  2013-11-18       Impact factor: 6.244

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.